Objective To evaluate the alterations of the monoamine concentration in the selective vesicular monoamine transporter 2 （VMAT2） deficient mice， and observe the symptoms of dopamine related Parkinson disease. Methods The VMAT2flox/+ mice （14 months） with a background of C57BL/6N were selected as the control group. The VMAT2-/+ mice （14 months） were developed by the Cre/loxP system to obtain conditional ablation of the Vmat2 gene specifically in the dopaminergic neurons， 50% of which were selected as the intervention group. A series of behavioral tests （14 male mice in each group） were carried out， and the monoamine neurotransmitters in the brain tissues of the two groups of mice （5-6 in each group） were detected by high performance liquid chromatography electrochemistry （HPLC-ED）. The correlation between dopamine and Parkinson disease was evaluated. Results Mice with selected ablation of the Vmat2 gene in dopaminergic neurons showed selective reduction of dopamine concentration in the brain， and with dysfunctions in motor and olfactory abilities， but no significant deficits of other non-motor functions， such as cognition， emotional performances and sleep patterns. Conclusions VMAT2 is closely related to Parkinson disease， and dopamine is more involved in the motor and olfactory performance of Parkinson disease， but may not be so strong associated with other non-motor symptoms， such as disturbances in emotion， cognition and sleep. This study implies potentially adjustment of therapeutic strategies of Parkinson disease.